Drugs / Bovis Calculus Stativus
Bovis Calculus Stativus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07240467 | Dec 2025 → Dec 2028 expected | ischemic stroke | Xiang Luo | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bovis Calculus Stativus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07240467 ↗ |
| Known as | BCS | “Cultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid,...” NCT07240467 ↗ |
| Known as | Cultivated Bovine Bezoar | “Cultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid,...” NCT07240467 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Cultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid,...” NCT07240467 ↗ |
| Route | Oral | “orally or via nasogastric tube” NCT07240467 ↗ |
| Route | Other | “orally or via nasogastric tube” NCT07240467 ↗ |